Alt, J.

Ball, P.

Heim, J. M.

Klohs, S.

Müller-Esch, G.

Potratz, J.

Scriba, Peter Christian

English

Open Access LMU

American Journal of Hypertension JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION THOMAS D. GILES New Orleans, Louisiana E D I T O R - I N - C H I E F JOHN H . LARAGH New York, New York E D I T O R S M I C H A E L A . WEBER Irvine, California N O R M A N M . KAPLAN Dallas, Texas D E P U T Y E D I T O R S LAWRENCE R. KRAKOFF LAWRENCE M . RESNICK New York, New York New York, Nezv York JOHN BAXTER San Francisco, California GERALD F.DlBONA Iowa City, Iowa C O N S U L T I N G E D I T O R S BARRY M . BRENNER Boston, Massachusetts JEANE. SEALEY New York, New York JAYN. C O H N Minneapolis, Minnesota E D H . SONNENBLICK New York, New York M . H . A L D E R M A N Neiu York, New York S . A . A T L A S New York, New York E . G . B I G L I E R I San Francisco, California D . M . B L A U F O X Neu> York, New York V . M . B U C K A L E W , J R . Winston Salem, North Carolina R R . B U H L E R Basle, Switzerland H . R . B R U N N E R Lausanne, Switzerland P.J. C A N N O N New York, New York R.M. C A R E Y Charlottesville, Virginia J. D E C H A M P L A I N Montreal, Canada R . J . C O D Y New York, New York A J . D E B O L D Ottawa, Canada E D I T O R I A L B O A R D R . B . D E V E R E U X Neiu York, New York M . E P S T E I N Miami, Florida W . F L A M E N B A U M Nezv York, New York W. F R I S H M A N New York, New York M . G O L D B E R G Philadelphia, Pennsylvania P. H A M E T Montreal, Canada M . H O R A N Bethesda, Maryland T. INAGAMI Nashville, Tennessee E. LIEBERMAN Los Angeles, California M . H . M A X W E L L Los Angeles, California D . A . M c C A R R O N Portland, Oregon M.I. NEW New York, New York M . H . P E R R Y Si. Louis, Missouri C. V. S. R A M Dallas, Texas D. J. REIS New York, New York D. SAVAGE Bethesda, Maryland J. A . S C H O E N B E R G E R Chicago, Illinois A. SINAIKO Minneapolis, Minnesota J .H. STEIN San Antonio, Texas D.H.P. S T R E E T E N Syracuse, New York L . T O B I A N Minneapolis, Minnesota P.M. VANHOUTTE Rochester, Minnesota B. R. WALKER Philadelphia, Pennsylvania M A N A G I N G E D I T O R J O A N B A N E S A m e r i c a n Society of H y p e r t e n s i o n , 515 M a d i s o n Avenue , Suite 2100, N e w York, N Y 10022 (212) 644-0650 VOLUME 1, NUMBER 3, PART 2, JULY 1988 American Journal of Hypertension J O U R N A L O F T H E A M E R I C A N S O C I E T Y O F H Y P E R T E N S I O N CONTENTS S P E C I A L A W A R D S 1 A A S H P R O G R A M S A S H A B S T R A C T S 6 A Cardiology 17A Pharmacology and Therapeutics 40A Endocrinology/Central Nervous System 54A Epidemiology 61A Electrolyte/Membrane Transport 68A Nephrology 80A Noninvasive Techniques 87A B A A P P R O G R A M Β A A P A B S T R A C T S 89A ANP: Peptide Synthesis, Storage, Release, and Metabolism 93A Cardiovascular and Neurological Actions of ANP 102A ANP and Renal Function 109A ANP and the Endocrine System 121A ANP Receptors and Second Messengers A M E R I C A N I O U R N A L OF HYPERTENSION (ISSN 0895-7061) is issued i n one volume i n four issues plus two special issues by Elsevier Science Publishing Co, Inc, 52 Vanderbilt Avenue, N e w York, NY 10017. Printed in the United States at Fame Avenue, Hanover, PA. Subscription prices per year: Institution, $98.00; individual , $49.00; interns and residents, $30.00. Outside of the US and possessions, please add $16.00 for surface delivery. Second class postage pending at N e w York, NY, and at additional mailing offices. POSTMASTER: Send address changes to A M E R I C A N JOURNAL OF HYPERTENSION, Elsevier Science Publishing Co, Inc, 52 Vanderbilt Avenue, N e w York, NY 10017. CONTENTS continued 128A ANP in Cardiovascular Disorders 135A ANP in Renal and Hepatic Disorders 140A ANP in Hypertension A U T H O R I N D E X E S 144A Third Annual Meeting of the American Society of Hypertension 149A Third Annual World Congress on Biologically Active Atrial Peptides GENERAL INFORMATION A M E R I C A N JOURNAL OF HYPERTENSION (ISSN 0895-7061) ( in-corporating JOURNAL OF C L I N I C A L HYPERTENSION) is issued i n one volume i n four issues plus two special issues by Elsevier Science Publishing Co., Inc., 52 Vanderbilt Avenue, N e w York, NY 10017. Subscription prices per year: Institution, $98.00; individual , $49.00; interns and residents, $30.00. Outside of the U.S. and possessions, please add $16.00 for surface delivery. Second class postage pending at New York, NY, and at additional mailing offices. Claims for missing issues can be honored only up to 3 months for domestic addresses and 6 months for foreign addresses. Duplicate copies w i l l not be sent to replace ones undelivered through failure to notify Elsevier Science Publishing Co., Inc., of a change of address. Single copy, microfi lm, and back volume information available f rom Elsevier Science Pub-lishing Co., Inc., upon request. Correspondence relating to manuscripts should be mailed to the Edi-torial office, Joan Banes, Managing Editor, 515 Madison Avenue, Suite 2100, N e w York, N Y 10022. Correspondence relating to advertising should be addressed to the A M E R I C A N JOURNAL OF HYPERTENSION, Advertising Office, 515 Madison Avenue, Suite 2100, N e w York, NY 10022. The A M E R I C A N JOURNAL OF HYPERTENSION is indexed/ab-stracted in Index Medicus, Current Contents, and Excerpta Medica. This journal has been registered w i t h the Copyright Clearance Center, Inc. Consent is given for the copying of articles for personal or internal nal use, or for the personal or internal use of specific clients. This consent is given on the condition that the copier pay through the Center the per copy fee stated i n the code on the first page of each article for copying beyond that permitted by the U.S. Copyright Law. I f no code appears on an article, the author has not given broad consent to copy, and permission to copy must be obtained directly f rom the author. This consent does not extend to other kinds of copy-ing, such as for general distribution, resale, advertising, and promo-tional purposes, or for creating new collective works. © 1988 by the American Journal of Hypertension, Inc. The appearance of advertising i n the A M E R I C A N JOURNAL OF H Y -PERTENSION does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made for i t by its manufacturer. The fact that a product, service, or company is adver-tised i n this publication shall not be referred to by the manufacturer i n collateral advertising. N o responsibility is assumed by the Publisher for any in jury and/or damage to persons or property as a matter of products l iability, negli-gence or otherwise, or f rom any use or operation of any methods, products, instructions or ideas contained i n the material herein. N o suggested test or procedure should be carried out unless, i n the readers' judgment, its risk is justified. Because of rapid advances i n the medical sciences, we recommend that the independent verification of diagnoses and drug dosages should be made. Discussions, views and recommendations as to medical procedures, choice of drugs and drug dosages are the responsibility of the authors. 9 4 A B I O L O G I C A L L Y A C T I V E A T R I A L PEPTIDES A) Η - JULY 7988-VOL. I NO. 3, PART 2 H e m o d y n a m i c a n d r e n a l effects of a t r i a l [5047 n a t r i u r e t i c p e p t i d e ( α - h A N P ) i n n o r m a l m a n G Müeller-Esch, J Potratz, J M H e i m , Ρ Ball , S Klohs , J Alt , a n d P C Scriba, Depts. of Medicine and Biochem. Endocrinology, Medical Univ., Lübeck, and Dept. Medicine, Univ. München, FRG W e studied the h e m o d y n a m i c a n d renal actions of a - h A N P in 7 heal thy volunteers . 200 μ of α - h A N P were given as an intravenous bolus injection. M-mode-echocardiography w a s performed a n d s e r u m levels of A N P a n d c G M P as wel l as c G M P - , s o d i u m - a n d potassium excretion were determined. W i t h i n 2 m i n , a transient heart rate increase of 34% to­gether w i t h a fall of m e a n arterial blood pressure of 11 % was observed. Stroke v o l u m e increased from 77.5 ± 1 5 . 1 to 90.3 ± 10.2 m l a n d cardiac index from 2.44 ± 0.41 to 2.88 ± 0.41 l / m 2 / m i n . Eject ion fraction rose from 62.9 ± 1.8 to 73.5 ± 3.8% (p < 0.01). H e m o d y n a m i c changes were most pronounced f rom 10 to 15 m i n after injection a n d reached baseline values another 15 m i n later. S e r u m A N P rose 20fold; c G M P rose 8fold w i t h i n the first 15 m i n a n d normalized after 1 hour. U r i n a r y c G M P excretion increased nearly 8fold, urine v o l u m e 9 fold, s o d i u m excretion 5 fold a n d potassium excretion doubled. T h e s e renal e f f e c t s — i n contrast to the hemody­n a m i c c h a n g e s — s h o w e d a m a x i m u m w i t h i n the first 30 min, but were still present for at least 90 m i n later. N o severe side effects were observed. Conclusions: I m p r o v e d myocardia l performance together w i t h sustained diuresis a n d natriuresis m a y be of therapeutical benefit i n the acute treatment of congestive heart failure. The role of c G M P as a marker for A N P action is confirmed. 

Hemodynamic and renal effects of atrial natriuretic peptide (a-hANP) in normal man.

Universität München: Elektronischen Publikationen

American 
Journal of 
Hypertension 
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION 
THOMAS D. GILES 
New Orleans, Louisiana 
E D I T O R - I N - C H I E F 
JOHN H . LARAGH 
New York, New York 
E D I T O R S 
M I C H A E L A . WEBER 
Irvine, California 
N O R M A N M . KAPLAN 
Dallas, Texas 
D E P U T Y E D I T O R S 
LAWRENCE R. KRAKOFF LAWRENCE M . RESNICK 
New York, New York New York, Nezv York 
JOHN BAXTER 
San Francisco, California 
GERALD F.DlBONA 
Iowa City, Iowa 
C O N S U L T I N G E D I T O R S 
BARRY M . BRENNER 
Boston, Massachusetts 
JEANE. SEALEY 
New York, New York 
JAYN. C O H N 
Minneapolis, Minnesota 
E D H . SONNENBLICK 
New York, New York 
M . H . A L D E R M A N 
Neiu York, New York 
S . A . A T L A S 
New York, New York 
E . G . B I G L I E R I 
San Francisco, California 
D . M . B L A U F O X 
Neu> York, New York 
V . M . B U C K A L E W , J R . 
Winston Salem, North Carolina 
R R . B U H L E R 
Basle, Switzerland 
H . R . B R U N N E R 
Lausanne, Switzerland 
P.J. C A N N O N 
New York, New York 
R.M. C A R E Y 
Charlottesville, Virginia 
J. D E C H A M P L A I N 
Montreal, Canada 
R . J . C O D Y 
New York, New York 
A J . D E B O L D 
Ottawa, Canada 
E D I T O R I A L B O A R D 
R . B . D E V E R E U X 
Neiu York, New York 
M . E P S T E I N 
Miami, Florida 
W . F L A M E N B A U M 
Nezv York, New York 
W. F R I S H M A N 
New York, New York 
M . G O L D B E R G 
Philadelphia, Pennsylvania 
P. H A M E T 
Montreal, Canada 
M . H O R A N 
Bethesda, Maryland 
T. INAGAMI 
Nashville, Tennessee 
E. LIEBERMAN 
Los Angeles, California 
M . H . M A X W E L L 
Los Angeles, California 
D . A . M c C A R R O N 
Portland, Oregon 
M.I. NEW 
New York, New York 
M . H . P E R R Y 
Si. Louis, Missouri 
C. V. S. R A M 
Dallas, Texas 
D. J. REIS 
New York, New York 
D. SAVAGE 
Bethesda, Maryland 
J. A . S C H O E N B E R G E R 
Chicago, Illinois 
A. SINAIKO 
Minneapolis, Minnesota 
J .H. STEIN 
San Antonio, Texas 
D.H.P. S T R E E T E N 
Syracuse, New York 
L . T O B I A N 
Minneapolis, Minnesota 
P.M. VANHOUTTE 
Rochester, Minnesota 
B. R. WALKER 
Philadelphia, Pennsylvania 
M A N A G I N G E D I T O R 
J O A N B A N E S 
A m e r i c a n Society of H y p e r t e n s i o n , 515 M a d i s o n Avenue , Suite 2100, N e w York, N Y 10022 (212) 644-0650 
VOLUME 1, NUMBER 3, PART 2, JULY 1988 
American 
Journal of 
Hypertension 
J O U R N A L O F T H E A M E R I C A N S O C I E T Y O F H Y P E R T E N S I O N 
CONTENTS 
S P E C I A L A W A R D S 
1 A A S H P R O G R A M S 
A S H A B S T R A C T S 
6 A Cardiology 
17A Pharmacology and Therapeutics 
40A Endocrinology/Central Nervous System 
54A Epidemiology 
61A Electrolyte/Membrane Transport 
68A Nephrology 
80A Noninvasive Techniques 
87A B A A P P R O G R A M 
Β A A P A B S T R A C T S 
89A ANP: Peptide Synthesis, Storage, Release, and Metabolism 
93A Cardiovascular and Neurological Actions of ANP 
102A ANP and Renal Function 
109A ANP and the Endocrine System 
121A ANP Receptors and Second Messengers 
A M E R I C A N I O U R N A L OF HYPERTENSION (ISSN 0895-7061) is issued i n one volume i n four issues plus two special 
issues by Elsevier Science Publishing Co, Inc, 52 Vanderbilt Avenue, N e w York, NY 10017. Printed in the United States 
at Fame Avenue, Hanover, PA. Subscription prices per year: Institution, $98.00; individual , $49.00; interns and 
residents, $30.00. Outside of the US and possessions, please add $16.00 for surface delivery. Second class postage 
pending at N e w York, NY, and at additional mailing offices. POSTMASTER: Send address changes to A M E R I C A N 
JOURNAL OF HYPERTENSION, Elsevier Science Publishing Co, Inc, 52 Vanderbilt Avenue, N e w York, NY 10017. 
CONTENTS continued 
128A ANP in Cardiovascular Disorders 
135A ANP in Renal and Hepatic Disorders 
140A ANP in Hypertension 
A U T H O R I N D E X E S 
144A Third Annual Meeting of the American Society of Hypertension 
149A Third Annual World Congress on Biologically Active Atrial Peptides 
GENERAL INFORMATION 
A M E R I C A N JOURNAL OF HYPERTENSION (ISSN 0895-7061) ( in-
corporating JOURNAL OF C L I N I C A L HYPERTENSION) is issued i n 
one volume i n four issues plus two special issues by Elsevier Science 
Publishing Co., Inc., 52 Vanderbilt Avenue, N e w York, NY 10017. 
Subscription prices per year: Institution, $98.00; individual , $49.00; 
interns and residents, $30.00. Outside of the U.S. and possessions, 
please add $16.00 for surface delivery. Second class postage pending 
at New York, NY, and at additional mailing offices. Claims for missing 
issues can be honored only up to 3 months for domestic addresses and 
6 months for foreign addresses. Duplicate copies w i l l not be sent to 
replace ones undelivered through failure to notify Elsevier Science 
Publishing Co., Inc., of a change of address. Single copy, microfi lm, 
and back volume information available f rom Elsevier Science Pub-
lishing Co., Inc., upon request. 
Correspondence relating to manuscripts should be mailed to the Edi-
torial office, Joan Banes, Managing Editor, 515 Madison Avenue, 
Suite 2100, N e w York, N Y 10022. 
Correspondence relating to advertising should be addressed to the 
A M E R I C A N JOURNAL OF HYPERTENSION, Advertising Office, 
515 Madison Avenue, Suite 2100, N e w York, NY 10022. 
The A M E R I C A N JOURNAL OF HYPERTENSION is indexed/ab-
stracted in Index Medicus, Current Contents, and Excerpta Medica. 
This journal has been registered w i t h the Copyright Clearance Center, 
Inc. Consent is given for the copying of articles for personal or internal 
nal use, or for the personal or internal use of specific clients. This 
consent is given on the condition that the copier pay through the 
Center the per copy fee stated i n the code on the first page of each 
article for copying beyond that permitted by the U.S. Copyright Law. 
I f no code appears on an article, the author has not given broad 
consent to copy, and permission to copy must be obtained directly 
f rom the author. This consent does not extend to other kinds of copy-
ing, such as for general distribution, resale, advertising, and promo-
tional purposes, or for creating new collective works. 
© 1988 by the American Journal of Hypertension, Inc. 
The appearance of advertising i n the A M E R I C A N JOURNAL OF H Y -
PERTENSION does not constitute a guarantee or endorsement of the 
quality or value of such product or of the claims made for i t by its 
manufacturer. The fact that a product, service, or company is adver-
tised i n this publication shall not be referred to by the manufacturer i n 
collateral advertising. 
N o responsibility is assumed by the Publisher for any in jury and/or 
damage to persons or property as a matter of products l iability, negli-
gence or otherwise, or f rom any use or operation of any methods, 
products, instructions or ideas contained i n the material herein. N o 
suggested test or procedure should be carried out unless, i n the 
readers' judgment, its risk is justified. Because of rapid advances i n the 
medical sciences, we recommend that the independent verification of 
diagnoses and drug dosages should be made. Discussions, views and 
recommendations as to medical procedures, choice of drugs and drug 
dosages are the responsibility of the authors. 
9 4 A B I O L O G I C A L L Y A C T I V E A T R I A L PEPTIDES A) Η - JULY 7988-VOL. I NO. 3, PART 2 
H e m o d y n a m i c a n d r e n a l effects of a t r i a l [5047 
n a t r i u r e t i c p e p t i d e ( α - h A N P ) i n n o r m a l m a n 
G Müeller-Esch, J Potratz, J M H e i m , Ρ Ball , S Klohs , J Alt , 
a n d P C Scriba, Depts. of Medicine and Biochem. 
Endocrinology, Medical Univ., Lübeck, and Dept. Medicine, 
Univ. München, FRG 
W e studied the h e m o d y n a m i c a n d renal actions of a - h A N P 
in 7 heal thy volunteers . 200 μ of α - h A N P were given as an 
intravenous bolus injection. M-mode-echocardiography w a s 
performed a n d s e r u m levels of A N P a n d c G M P as wel l as 
c G M P - , s o d i u m - a n d potassium excretion were determined. 
W i t h i n 2 m i n , a transient heart rate increase of 34% to­
gether w i t h a fall of m e a n arterial blood pressure of 11 % was 
observed. Stroke v o l u m e increased from 77.5 ± 1 5 . 1 to 
90.3 ± 10.2 m l a n d cardiac index from 2.44 ± 0.41 to 2.88 ± 
0.41 l / m 2 / m i n . Eject ion fraction rose from 62.9 ± 1.8 to 
73.5 ± 3.8% (p < 0.01). H e m o d y n a m i c changes were most 
pronounced f rom 10 to 15 m i n after injection a n d reached 
baseline values another 15 m i n later. S e r u m A N P rose 20fold; 
c G M P rose 8fold w i t h i n the first 15 m i n a n d normalized after 
1 hour. U r i n a r y c G M P excretion increased nearly 8fold, urine 
v o l u m e 9 fold, s o d i u m excretion 5 fold a n d potassium excretion 
doubled. T h e s e renal e f f e c t s — i n contrast to the hemody­
n a m i c c h a n g e s — s h o w e d a m a x i m u m w i t h i n the first 30 min, 
but were still present for at least 90 m i n later. N o severe side 
effects were observed. 
Conclusions: I m p r o v e d myocardia l performance together 
w i t h sustained diuresis a n d natriuresis m a y be of therapeutical 
benefit i n the acute treatment of congestive heart failure. The 
role of c G M P as a marker for A N P action is confirmed. 


https://epub.ub.uni-muenchen.de/8597/1/8597.pdf

Hemodynamic and renal effects of atrial natriuretic peptide (a-hANP) in normal man.

Abstract

Similar works

Full text

Available Versions

Open Access LMU

Universität München: Elektronischen Publikationen